BioVie Announces The Appointment Of Industry Veterans Dr. Amy Chappell And Kameel Farag To Its Board Of Directors

BioVie Inc., a clinical-stage company focused on developing innovative therapies for neurological, neurodegenerative, and advanced liver diseases, has announced the appointment of two new members to its Board of Directors: Dr. Amy S. Chappell and Kameel D. Farag. These appointments come as the company continues to advance its clinical programs and strengthen its leadership team during a period of significant progress. Dr. Amy S. Chappell brings extensive experience in clinical neuroscience and drug development. Over her 25-year career at Eli Lilly & Co., she played a critical role in the development and FDA approval of multiple therapies targeting central nervous system (CNS) conditions, including Cymbalta® for fibromyalgia and musculoskeletal pain. 

Following her time at Lilly, she served as Chief Medical Officer at Eliem Therapeutics, where she supported the company through a successful IPO and advanced drug programs focused on epilepsy and mood disorders. She is currently the Chief Medical Officer of Solaxa Inc., where she oversees clinical development efforts in ataxia and nerve repair. Dr. Chappell holds numerous patents, has authored over 100 scientific publications and presentations, and is a Fellow of the American Academy of Neurology.

Kameel D. Farag is an experienced executive in the biotechnology and finance sectors, with a strong track record in strategic leadership and operational growth. As Chief Financial Officer and head of business operations at Aspen Neuroscience, he led efforts that tripled the company's workforce, secured over \$150 million in funding, established key manufacturing infrastructure, and positioned the company for future clinical and public milestones. He has also held senior financial leadership roles at Ionis Pharmaceuticals and Amgen, where he played a key role in expanding international operations and driving revenue growth outside the U.S.

Cuong Do, President and Chief Executive Officer (CEO) of BioVie Inc, said in a statement, “Amy and Kameel each bring an extraordinary combination of strategic vision, operational excellence, and hands-on experience developing and commercializing therapies in complex neurological and chronic diseases. As BioVie continues to advance bezisterim through Phase 2 trials for early Parkinson’s disease and long COVID, and plans the next steps in clinical development in our Alzheimer’s disease and ascites programs, their expertise will be invaluable in achieving our mission of transforming the treatment of these devastating conditions.”

Their appointments coincide with a period of momentum for BioVie. The company recently presented encouraging data on its investigational therapy bezisterim at the 7th World Aging and Rejuvenation Conference, highlighting its potential to slow or even reverse biological aging and neurodegeneration. In addition, BioVie has launched its Phase 2 ADDRESS-LC trial targeting long COVID and is continuing development of its SUNRISE-PD study for Parkinson’s disease. These additions to the Board are expected to further support BioVie’s mission to deliver patient-centered innovation and move closer to offering transformative therapies in areas of high unmet need.